| NCCN guidelines insights: soft tissue sarcoma, version 1.2021: featured updates to the NCCN guidelines M von Mehren, JM Kane, MM Bui, E Choy, M Connelly, S Dry, KN Ganjoo, ... Journal of the National Comprehensive Cancer Network 18 (12), 1604-1612, 2020 | 220 | 2020 |
| Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology M von Mehren, JM Kane, M Agulnik, MM Bui, J Carr-Ascher, E Choy, ... Journal of the National Comprehensive Cancer Network 20 (7), 815-833, 2022 | 118 | 2022 |
| Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases NL Williams, EJ Wuthrick, H Kim, JD Palmer, S Garg, H Eldredge-Hindy, ... International Journal of Radiation Oncology* Biology* Physics 99 (1), 22-30, 2017 | 110 | 2017 |
| MMAD: microarray microdissection with analysis of differences is a computational tool for deconvoluting cell type-specific contributions from tissue samples DA Liebner, K Huang, JD Parvin Bioinformatics 30 (5), 682-689, 2014 | 89 | 2014 |
| Thyroid cancer: pathogenesis and targeted therapy DA Liebner, MH Shah Therapeutic advances in endocrinology and metabolism 2 (5), 173-195, 2011 | 82 | 2011 |
| TP53 mutational status is predictive of pazopanib response in advanced sarcomas K Koehler, D Liebner, JL Chen Annals of Oncology 27 (3), 539-543, 2016 | 70 | 2016 |
| Treatment of ipilimumab induced Graves’ disease in a patient with metastatic melanoma U Azmat, D Liebner, A Joehlin-Price, A Agrawal, F Nabhan Case Reports in Endocrinology 2016, 2016 | 63 | 2016 |
| A network model for dispersion of communicable diseases L Bian, D Liebner Transactions in GIS 11 (2), 155-173, 2007 | 59 | 2007 |
| Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas. SP Chawla, KN Ganjoo, S Schuetze, Z Papai, BA Van Tine, E Choy, ... Journal of Clinical Oncology 35 (15_suppl), 11000-11000, 2017 | 49 | 2017 |
| Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors. DS Hong, BA Van Tine, AJ Olszanski, ML Johnson, DA Liebner, T Trivedi, ... Journal of Clinical Oncology 38 (15_suppl), 102-102, 2020 | 47 | 2020 |
| Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients CM Cebulla, EM Binkley, R Pilarski, JB Massengill, K Rai, DA Liebner, ... Ophthalmic genetics 36 (2), 126-131, 2015 | 47 | 2015 |
| The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma DA Liebner Journal of Surgical Oncology 111 (5), 622-631, 2015 | 44 | 2015 |
| Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial DS Hong, BA Van Tine, S Biswas, C McAlpine, ML Johnson, AJ Olszanski, ... Nature medicine 29 (1), 104-114, 2023 | 43 | 2023 |
| A multicenter phase II study of nivolumab+/-ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts. JL Chen, MR Mahoney, S George, CR Antonescu, DA Liebner, ... Journal of Clinical Oncology 38 (15_suppl), 11511-11511, 2020 | 42 | 2020 |
| Inflammatory myofibroblastic tumor driven by novel NUMA1-ALK fusion responds to ALK inhibition N Rao, H Iwenofu, B Tang, J Woyach, DA Liebner Journal of the National Comprehensive Cancer Network 16 (2), 115-121, 2018 | 31 | 2018 |
| Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib DA Liebner, SA Walston, R Cavaliere, CJ Powers, E Sauvageau, ... Melanoma research 24 (2), 172-176, 2014 | 31 | 2014 |
| Angiosarcoma: a rare malignancy with protean clinical presentations JT Huntington, C Jones, DA Liebner, JL Chen, RE Pollock Journal of surgical oncology 111 (8), 941-950, 2015 | 26 | 2015 |
| Patterns of major wound complications following multidisciplinary therapy for lower extremity soft tissue sarcoma ED Miller, X Mo, NT Andonian, KE Haglund, DD Martin, DA Liebner, ... Journal of surgical oncology 114 (3), 385-391, 2016 | 25 | 2016 |
| NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022: Featured Updates to the NCCN Guidelines M von Mehren, JM Kane, RF Riedel, JK Sicklick, SM Pollack, M Agulnik, ... Journal of the National Comprehensive Cancer Network 20 (11), 1204-1214, 2022 | 22 | 2022 |
| A randomized, double‐blind, placebo‐controlled, phase II study of regorafenib versus placebo in advanced/metastatic, treatment‐refractory liposarcoma: results from the sarc024 … RF Riedel, KV Ballman, Y Lu, S Attia, ET Loggers, KN Ganjoo, ... The Oncologist 25 (11), e1655-e1662, 2020 | 21* | 2020 |
Gabriel Tinoco, MD FACPAssociate Professor of Medicine Ohio State UniversityZweryfikowany adres z osumc.edu
